Breaking News, Collaborations & Alliances

Roche’s MabThera Launch Triggers $5M Halozyme Milestone

Marks second product to use Halozyme's Enhanze technology

Roche’s MabThera SC has launched in Europe, triggering a $5 million milestone payment to Halozyme Therapeutics under the companies’ license and collaboration agreement. In addition to Herceptin SC, MabThera SC is the second subcutaneous formulation of one of Roche’s oncology products to use Halozyme’s Enhanze (recombinant human hyaluronidase) technology.
 
MabThera SC is approved for the treatment of patients with follicular lymphoma and diffuse large B-cell lymphoma. This formulation could potentially save time for patients, physicians and health care providers.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters